UNIVERSAL-WELLNESS-LABS
5.5.2021 14:21:06 CEST | Business Wire | Press release
Digital Health Certificates are happening. Governments, airlines and the industry at large need solutions to get the people moving freely and safely. Universal Wellness Labs creates a wearable for hand cleaning that holds the QR-code for Health Certificates. The user-friendly gadget serves as an alternative medium, and as a back-up for the QR-codes in smartphone apps or printed on paper.
Health Certificates, a.k.a. Immunity Passports, Vaccine Certificates, Green Passes and PCR tests come as QR-code for storage in apps in people’s smartphones or printed on paper.
Universal Wellness Labs foresees potential issues and uses NFC as a medium for the QR.
It pairs the Health Certificate with hand hygiene in one useful and user-friendly wearable dispenser for hand sanitizer: the Zpritzi.
Marinus Vander Slikke, CEO of Universal Wellness Labs: “A document as vital as a Health Certificate must have a back-up. Apps can crash. Smartphones can die. Paper-printed QR-codes are old world, prone to forgery and get lost easily.”
NFC is secure, contactless and works without electronics and networks.
A video-presentation of the Zpritzi concept is available at www.zpritzi.com .
Universal Wellness Labs recently presented its concept to the European Commission.
Marinus Vander Slikke: “We anticipate deeper negotiations soon. Sweden and Denmark have already endorsed NFC. However, we are also targeting the private sector like airlines, hotels, cruise ships and event organisers.”
Zpritzi is a slim, elongated and ergonomic designed wearable gadget. Made from recyclable ABS. Refillable with any sanitizer spray. An integrated encrypted NFC tag stores the QR-code. People wear it around their neck, or on their belt or hand-bag.
Zpritzi is low-cost and an ideal product for corporate branding: It verifies people’s health status, makes hand disinfection easy and is a promotional tool with lasting marketing effects.
A pilot study with 88 participants shows the efficacy of the Zpritzi. Users clean their hands 75% more often with a Zpritzi than with conventional portable bottles.
Marinus Vander Slikke: “Hand cleaning is a first line of defence against any kind of bacteria and viruses, including Covid. Both the public and the private sector require proof of health to enter their country or premises. A quick scan of the Zpritzi verifies people’s health status. And the big advantage is that people always go in with clean hands.”
“In the new normal people still want to be trendy and look smart. Similar to face masks, Zpritzi makes the Health Certificate and hand sanitizing cool.”
Zpritzi is created in cooperation with Design2Gather, an award winning Dutch design company (design2gather.com ).
Universal Wellness Labs OÜ is an Estonia based company that conceptualizes and designs products for personal health and wellness (universalwellnesslabs.com ).
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005604/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom